Docoh
Loading...

PKI Perkinelmer

News

Pro users get this 30m faster
PerkinElmer Says Co's Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test Is Used In UK COVID-19 Human Challenge Study To Investigate T Cell Response To SARS-CoV-2 Infection
18 May 21
News, FDA
Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer, today announced that its T-SPOT® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human
PerkinElmer To Acquire UK-Based In-Vitro Diagnostics Company For $155M
17 May 21
Biotech, M&A, News, Health Care, General
PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition
13 May 21
M&A, News, Health Care, General
PerkinElmer To Acquire Nexcelom Bioscience For $260M In Cash
12 May 21
M&A
WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc. (NYSE:PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is expected to close during
PerkinElmer Unit, Oxford Immunotec, Reports Its T-SPOT COVID Test Will Be Used For T Cell Testing In COVID Infection in Patients with Antibody Deficiency Study In Collab With University Of Birmingham
11 May 21
News
Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer, announced that its T-SPOT®.COVID test will be used for T cell testing in the COV-AD (COVID infection in patients with Antibody
Why PerkinElmer's Stock Is Trading Higher Today
5 May 21
Movers, Trading Ideas
PerkinElmer's (NYSE:PKI) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also raised its FY21 EPS and sales guidance.
PerkinElmer: Q1 Earnings Insights
4 May 21
Earnings
Shares of PerkinElmer (NYSE:PKI) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 455.22% year over year to $3.72, which beat the estimate of $3.07.
PerkinElmer Q1 Adj. EPS $3.72 Beats $3.07 Estimate, Sales $1.31B Beat $1.21B Estimate; Raises FY Guidance
4 May 21
Earnings, News, Guidance
PerkinElmer (NYSE:PKI) reported quarterly earnings of $3.72 per share which beat the analyst consensus estimate of $3.07 by 21.17 percent. This is a 455.22 percent increase over earnings of $0.67 per share from the same
P/E Ratio Insights for PerkinElmer
4 May 21
Earnings, News, Intraday Update, Markets
Earnings Scheduled For May 4, 2021
4 May 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.
Earnings Scheduled For May 3, 2021
3 May 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Scienjoy Holding (NASDAQ:SJ) is estimated to report quarterly earnings at $0.58 per share on revenue of $540.11 million.
PerkinElmer Sees Reported Revenue Growth For Q1 Of 98%; Core (Non-COVID) Demand Up 10% Organically YoY
13 Apr 21
News, Guidance
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for
PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface
29 Mar 21
News, FDA
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference CRISPRi Innovations Provide Expanded Experimental Options and

Press releases

Pro users get this 30m faster
Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection
18 May 21
Health Care, Press Releases
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer, today announced that its T-SPOT® Discovery
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
17 May 21
Press Releases
Endocrinology testing specialist expands PerkinElmer's immunodiagnostics segment PerkinElmer, Inc. (NYSE:PKI) ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC (LSE: IHS) ("IDS") are pleased to announce that
PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience
12 May 21
Press Releases
Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing PerkinElmer, Inc. (NYSE:PKI) is pleased to
Oxford Immunotec's T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency
11 May 21
Health Care, Press Releases, General
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer, announced that its T-SPOT®.COVID test will be used
PerkinElmer to Host Virtual Investor and Analyst Day
4 May 21
Press Releases
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to
PerkinElmer Announces Financial Results for the First Quarter of 2021
4 May 21
Press Releases
Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings
PerkinElmer Announces Financial Results for the First Quarter of 2021
4 May 21
Press Releases
Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings
PerkinElmer, Inc. (United States) to Host Earnings Call
4 May 21
Earnings, News, Press Releases
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / PerkinElmer, Inc. (United States) (NYSE:PKI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 5:00 PM Eastern
PerkinElmer Board Declares Quarterly Dividend
29 Apr 21
Press Releases
The Board of Directors of PerkinElmer, Inc. (NYSE:PKI), declared a regular quarterly dividend of $0.07 per share of common stock April 29, 2021. This dividend is payable on August 6, 2021 to all shareholders of record
Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
29 Apr 21
Health Care, Press Releases
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer (NYSE:PKI), today announced that its T-SPOT®
Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
27 Apr 21
Health Care, Press Releases, General
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer (NYSE:PKI), today announced that its T-SPOT®
PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference
21 Apr 21
Press Releases
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12,
PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021
13 Apr 21
Press Releases
Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference
29 Mar 21
Press Releases
CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its